Sana Biotechnology SANA Change In Fair Value Of Success Payment Liabilities
Change In Fair Value Of Success Payment Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept sana:ChangeInFairValueOfSuccessPaymentLiabilities.
The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sana Biotechnology's change in fair value of success payment liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sana Biotechnology's change in fair value of success payment liabilities?
- Sana Biotechnology (SANA) reported change in fair value of success payment liabilities of -$2.31M in Q1 2026.
- How has Sana Biotechnology's change in fair value of success payment liabilities changed year-over-year?
- Sana Biotechnology's change in fair value of success payment liabilities decreased by 2586.0% year-over-year, from $93K to -$2.31M.
- What is the long-term trend for Sana Biotechnology's change in fair value of success payment liabilities?
- Over 2 years (2022 to 2025), Sana Biotechnology's change in fair value of success payment liabilities has grown at a -58.1% compound annual growth rate (CAGR), from -$83.71M to $14.68M.
- What does change in fair value of success payment liabilities mean?
- This metric captures the non-cash periodic adjustments to the fair value of liabilities associated with success-based payments, often linked to clinical or regulatory milestones. Fluctuations in this value indicate changes in the market's or management's valuation of the likelihood that specific therapeutic programs will reach defined success criteria. It provides insight into the volatility of long-term financial obligations tied to R&D progress.